LIVE FROM MD&M WEST: Minntech employs Eastman Tritan in renal market
The first acute renal care market manufacturer to utilize Eastman Chemical Co.’s (www.eastman.com/tritan) Tritan™ copolyester, the Therapeutic Technologies Group of Minntech Corp., a Cantel Medical company, is developing the first renal system applications made with Tritan--Hemocor HPH® Hemoconcentrators and Renaflo® II Hemofilters.
The announcement was made Feb. 8 at the Medical Design & Manufacturing West trade show in Anaheim, CA.
The Hemocor HPH Hemoconcentrator is a fluid-removal device used in
cardio bypass surgery. The Renaflo II Hemofilter is used in intensive
care units for treatment of acute renal failure, including fluid removal
and kidney stabilization procedures. Both devices will be available
following regulatory submission and approval.
Minntech’s Therapeutic Technologies Group selected Eastman Tritan™
copolyester for these devices due to the material’s secondary operations
capacities that allow solvent bonding and the potential to reduce cost
and processing time. The material also offers clarity and is BPA-free.
The high-flow attribute of Tritan made it possible for Minntech to
utilize existing molds to create the new products.
“It’s a priority that individuals in the healthcare industry are
confident in the quality and reliability of our products,” said Randy
Wenthold, vice president, Therapeutic Technologies Group, Minntech. “We
believe being among the first to market with these devices featuring the
high-quality attributes Eastman Tritan™ copolyester offers is in line
with our reputation as an industry leader that provides cutting-edge